PHARMACOR LURASIDONE lurasidone hydrochloride 20 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor lurasidone lurasidone hydrochloride 20 mg film-coated tablet blister pack

pharmacor pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; citric acid; lactose monohydrate; mannitol; magnesium stearate; povidone; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

PHARMACOR LURASIDONE lurasidone hydrochloride 20 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor lurasidone lurasidone hydrochloride 20 mg film-coated tablet bottle

pharmacor pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: povidone; mannitol; pregelatinised maize starch; lactose monohydrate; citric acid; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

DOMION agomelatine 25 mg film-coated tablet blister pack. Australia - English - Department of Health (Therapeutic Goods Administration)

domion agomelatine 25 mg film-coated tablet blister pack.

servier laboratories (aust) pty ltd - agomelatine, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; stearic acid; colloidal anhydrous silica; sodium starch glycollate type a; maize starch; lactose monohydrate; propylene glycol; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution; indigo carmine aluminium lake; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; glycerol - treatment in adults of: - of major depression (mdd) including prevention of relapse - generalised anxiety disorder (gad)

VALDOXAN agomelatine 25 mg film coated tablet blister pack. Australia - English - Department of Health (Therapeutic Goods Administration)

valdoxan agomelatine 25 mg film coated tablet blister pack.

servier laboratories (aust) pty ltd - agomelatine, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; stearic acid; colloidal anhydrous silica; sodium starch glycollate type a; maize starch; lactose monohydrate; propylene glycol; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution; indigo carmine aluminium lake; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; glycerol - treatment in adults of: - of major depression (mdd) including prevention of relapse - generalised anxiety disorder (gad)

Cobisomyl 5mg/12.5mg film-coated Tablets Malta - English - Medicines Authority

cobisomyl 5mg/12.5mg film-coated tablets

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - hydrochlorothiazide, bisoprolol fumarate - film-coated tablet - bisoprolol fumarate 5 mg hydrochlorothiazide 12.5 mg - beta blocking agents

Cobisomyl 10mg/25mg film-coated Tablets Malta - English - Medicines Authority

cobisomyl 10mg/25mg film-coated tablets

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - hydrochlorothiazide, bisoprolol fumarate - film-coated tablet - hydrochlorothiazide 25 mg bisoprolol fumarate 10 mg - beta blocking agents

APO-OLMESARTAN/AMLODIPINE/HCTZ 40/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/12.5 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 40/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/12.5 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 6.95 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; pregelatinised maize starch; magnesium stearate; povidone; lactose monohydrate; silicified microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/5/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

APO-OLMESARTAN/AMLODIPINE/HCTZ 40/5/25 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/25 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 40/5/25 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/25 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: povidone; pregelatinised maize starch; silicified microcrystalline cellulose; lactose monohydrate; magnesium stearate; isopropyl alcohol; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/5/25 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

APO-OLMESARTAN/AMLODIPINE/HCTZ 40/10/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/12.5 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 40/10/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/12.5 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.9 mg; hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/10/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

APO-OLMESARTAN/AMLODIPINE/HCTZ 20/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 20/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; magnesium stearate; lactose monohydrate; povidone; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - apo-olmesartan/amlodipine/hctz 20/5/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.